Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899660 | 0.99 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19914393 | 0.89 | FAAH (0.40) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19899596 | 0.83 | ESR1 (0.44) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL19899642 | 0.83 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19899502 | 0.83 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19899666 | 0.83 | S1PR3 (0.51) | RAB9AMEN1MAPTKMT2AGAA | |
| SCHEMBL19899531 | 0.82 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19914359 | 0.82 | NPBWR1 (0.41) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19899788 | 0.80 | CSNK2A2 (0.34) | NPC1RAB9ASMN1; SMN2NPSR1MAPT | |
| SCHEMBL19900225 | 0.80 | ALDH1A1 (0.40) | NPC1RAB9ASMN1; SMN2NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | claimed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | claimed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | claimed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | NPC1 114/4885RAB9A 1688/4885SMN1; SMN2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.